Short interest for Bio-Rad Laboratories gives investors a sense of the degree to which investors are betting on the decline of Bio-Rad Laboratories's stock. Short interest data is updated every two weeks.

Bio-Rad Laboratories Stock (NYSE:BIO), Short Interest Report

Bio-Rad Laboratories

Bio-Rad Laboratories Inc manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. It operates in two industry segments; In Clinical Diagnostics segment, the company manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In Life Sciences segment, the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with majority of the revenue being generated from United States, it also has its presence in Europe, Asia, Canada and other regions.

bulls ai

Biotech

Equities

Large Cap

Mid Cap

Short Sellers

Broad U.S. Equity ETFs

Price Target

Travel

Tech

ETFs

XLRE

480 out of 500 S&amp;P 500 companies are trading below analysts&#39; price targets, indicating potential profit opportunities. April has been bleak for the market, but some undervalued stocks may be worth buying. Top 5 stocks with biggest gap between price and target: CCL, BIO, WBD, CZR, CCO.

96% Of S&amp;P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?

Wall Street

Analyst Color

Small Cap

Economics

Federal Reserve

Intraday Update

Markets

Analyst Ratings

Movers

AMAT

AMZN

COIN

DASH

SPDR Dow Jones Industrial Average ETF Trust

KNSL

MSFT

ROKU

SWAV

TOST

Wall Street takes pause after stronger-than-expected producer inflation report, potentially delaying Fed rate cuts and impacting major indices and stocks.

Tech Stocks Ease On Hot PPI, Yields Rise, Microsoft, Amazon Snap 5-Week Positive Streak: What&#39;s Driving Markets Friday?

News

Trading Ideas

AORT

BLZE

GYRE

NNOX

NYAX

PRAA

SRPT

TXRH

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.

Applied Materials Posts Upbeat Earnings, Joins Texas Roadhouse, Vulcan Materials And Other Big Stocks Moving Higher On Friday

Bio-Rad Laboratories, Inc. Class A Common Stock

Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. Class B Common Stock

BIOASIS TECHNOLOGIES INC by Bioasis Technologies Inc.

Bioasis Technologies Inc

Biocept Inc COM PAR $0.0001 NEW 2023

Biocept Inc

Bio Essence Corp

Blue Biofuels Inc

Biocartis Group NV

BioGaia AB

Biome Grow Inc

Biolase Inc

BIONITROGEN HLDGS CORP by BioNitrogen Holdings Corp.

BioNitrogen Holdings Corp

Bioqual Inc

Biora Therapeutics Inc

BioPassport Token

SWEDISH ORPHAN BIOVIT ORD by Swedish Orphan Biovitrum AB

Swedish Orphan Biovitrum AB

Bioceres Crop Solutions Corp. - Ordinary Shares

Bioceres Crop Solutions Corp

Biosyent Inc

WIIM

ILMN

Shares of life sciences tools stocks are trading higher following strong earnings from Danaher.

Bio-Rad Laboratories Inc Reports 8.99% Passive Stake In Oncocyte Corp As Of April 15, 2024

Ninety-six percent, or 480 out of the 500 companies comprising the S&amp;P 500 index, are trading at lower market values compared to Wall Street analysts&#8217; price targets, signaling abundant potential <a href="https://www.benzinga.com/markets">profit opportunities for investors.</a>
Thus far, April has marked the bleakest month for the U.S. stock market since September 2023, with the S&amp;P 500 index, tracked by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), falling by 3.7%.
Across all 11 sectors constituting the index, only the Energy Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) has managed to evade losses. The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) emerged as the month&#8217;s weakest performer, experiencing a 10% downturn.
Higher-than-expected inflation figures have placed downward pressure on stocks, leading to reduced expectations for Federal Reserve rate cuts. As of April 18, investors expect fewer than two rate cuts, down from over three anticipated at the beginning of the month.
Simultaneously, mounting geopolitical risks stemming from the ongoing Middle East crisis have amplified market uncertainties.
However, this phase of increased volatility has subdued the once prevalent bullish sentiment that persisted until the end of March, uncovering attractive opportunities for investors who favor buying the dips of undervalued stocks.
Presented herein are the top 5 contrarian stocks within the S&amp;P 500 index exhibiting the most pronounced relative gap between current market prices and median price targets.
<h3 class="wp-block-heading">5. Carnival Corporation</h3>
Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) has experienced a noticeable downturn, dropping by 11.54% this month and 22.03% year-to-date. 
Analysts, however, have maintained consistency in their price forecasts. At the beginning of the year, the median target was $20.78, which has since held steady at $22. 
This suggests a substantial 52.20% potential upside from the current trading price of $14.46 per share.
<h3 class="wp-block-heading">4. Bio-Rad Laboratories, Inc.</h3>
Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) has witnessed an 18.81% decline in price this month and a 13.03% decrease year-to-date. 
Despite market fluctuations, the median price target has remained unchanged at $436.70 since the beginning of 2024.
Presently trading at $280.81 per share, this implies that analysts see a potential upside of 55.51% if the stock price converges with the target.
<h3 class="wp-block-heading">3. Warner Bros. Discovery, Inc.</h3>
Warner Bros. Discovery, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) has declined 5.27% this month and by a substantial 27.33% year-to-date. 
Analysts have downwardly adjusted their price targets for WBD shares, reducing the median level from $16.64 at the beginning of the year to $13 presently. 
Despite these downward revisions, the current share price of $8.27 still provides some margin of safety to investors, indicating a potential 57.19% upside if it converges with analysts&#8217; targets.
<h3 class="wp-block-heading">2. Caesars Entertainment Inc. </h3>
Caesars Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NYSE">CZR</a>) has declined by 11.25% month-to-date and a more substantial 17.19% year-to-date. 
However, despite these negative trends, analysts have made minimal adjustments to their price targets for the casino-related company. 
With the current trading price at $38.32, the median price target of $62.50 suggests a significant profit potential of 61% if the current price aligns with analysts&#8217; expectations.
<h3 class="wp-block-heading">1. Globe Life Inc. </h3>
Globe Life Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GL#NYSE">GL</a>) faced a tumultuous April, plummeting by a staggering 50% due to a critical report by short seller Fuzzy Panda Research. 
Despite this, since hitting its lows on April 11, the shares have rebounded by 66%, though remaining still well below pre-report levels. 
Despite a slight reduction in Wall Street analysts&#8217; price targets, down from $136 to $130 in the past month, the current stock price of $64.98 presents an enticing short-squeeze opportunity, suggesting a profit potential of 100% if investors can counter and push back against Fuzzy Panda&#8217;s bearish pressure. 
Chart: Will Globe Life Be Able To Squeeze Short Sellers?
<figure class="wp-block-image size-large"><img loading="lazy" decoding="async" width="1024" height="495" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-1024x495.png" alt="" class="wp-image-298332" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-1024x495.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-300x145.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-768x372.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122-1536x743.png 1536w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/04/18120911/image-122.png 1920w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Name</td>
<td>Price Target vs. Last Price</td>
<td>Last Price</td>
<td>Price Target &#8211; Median</td>
<td>Price Median 1Month Ago)</td>
<td>Price Target (2024 start)</td>
<td>Price Chg. % (MTD)</td>
<td>Price Chg. % (YTD)</td>
</tr>
<tr>
<td>Globe Life Inc.</td>
<td>100.05%</td>
<td>64.98</td>
<td>130.00</td>
<td>136.00</td>
<td>133.56</td>
<td>-44.16%</td>
<td>-46.61%</td>
</tr>
<tr>
<td>Caesars Entertainment, Inc.</td>
<td>61.00%</td>
<td>38.82</td>
<td>62.50</td>
<td>63.00</td>
<td>62.33</td>
<td>-11.25%</td>
<td>-17.19%</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc.</td>
<td>57.19%</td>
<td>8.27</td>
<td>13.00</td>
<td>13.20</td>
<td>16.64</td>
<td>-5.27%</td>
<td>-27.33%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories, Inc.</td>
<td>55.51%</td>
<td>280.81</td>
<td>436.70</td>
<td>436.70</td>
<td>436.67</td>
<td>-18.81%</td>
<td>-13.03%</td>
</tr>
<tr>
<td>Carnival Corporation &amp; plc</td>
<td>52.20%</td>
<td>14.46</td>
<td>22.00</td>
<td>22.00</td>
<td>20.78</td>
<td>-11.54%</td>
<td>-22.03%</td>
</tr>
</tbody>
</table>
</figure>
Read now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/04/38303079/most-s-p-500-stocks-no-longer-trade-above-50-day-average-healthy-pullback-or-is-the">Most S&amp;P 500 Stocks No Longer Trade Above 50-Day Average: Healthy Pullback Or Is The Bull Market Over? </a>
Image generated using artificial intelligence via Midjourney.

96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?

The new product is expected to launch in&nbsp;Q2&nbsp;2024 to a select group of academic transplant centers in the US and EU and more broadly in the second half of the year.&nbsp;As part of the agreement, Bio-Rad and Oncocyte will co-market the assay inside the US and Germany, with Oncocyte acting as commercial lead. Outside these countries Bio-Rad has been granted exclusive global distribution and commercial rights.&nbsp;Additionally, Bio-Rad has been granted an option for IVD commercial rights at FDA clearance

Contracts

Oncocyte Announces Partnership Agreement With Bio-Rad Laboratories On Global Launch Of Transplant Assay; Bio-Rad Expects To Make Equity Investment In Support Of Deal

Last will remain part of Bio-Rad&#39;s executive leadership team to ensure a smooth transition while the company conducts a search for his successor.

Management

Bio-Rad Laboratories Says Andrew Last, Executive Vice President And COO, Is Planning To Retire By Early September Of 2024

Citigroup analyst Patrick Donnelly downgrades Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) from Buy to Neutral and lowers the price target from $400 to $365.

Downgrades

Citigroup Downgrades Bio-Rad Laboratories to Neutral, Lowers Price Target to $365

Bio-Rad Appoints Roop Lakkaraju As Executive Vice President And CFO effective April 15, 2024

Wall Street paused for a breather Friday following a stronger-than-anticipated producer inflation report that once again caught investors off guard, echoing the heat of a similarly strong consumer inflation report <a href="https://www.benzinga.com/topic/inflation">earlier in the week</a>.
The Producer Price Index (PPI) for January 2024 saw a 0.3% month-over-month increase, surpassing the projected 0.1% surge, while the Consumer Price Index (CPI) surged by 3.1% year-on-year, exceeding the forecasted 2.9%, highlighting the ongoing intensity <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/02/37178834/producer-inflation-outruns-expectations-in-january-chills-investor-bets-on-fed-rate-cu">of the inflation battle.</a>
&#8220;The January inflation data vindicates the Fed&#8217;s wait-and-see approach,&#8221; Bank of America economist Stephen Juneau said in a note. 
As a result, traders trimmed their expectations for Fed rate cuts, delaying the anticipated start to this summer. Yields surged higher, with the policy-sensitive two-year note yield climbing by over 10 basis points to reach 4.67%. 
As of noon trading in New York, the S&amp;P 500 showed minimal change for the day, while the tech-heavy Nasdaq 100 lagged behind, potentially ending a five-week winning streak. A similar trend was observed with both Microsoft Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NYSE">MSFT</a>) and Amazon.com Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>)
<h2 class="wp-block-heading">Friday's Performance In Major Indices, ETFs</h2>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices &amp; ETFs</td>
<td>Price</td>
<td>1-day % chg</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,020.44</td>
<td>-0.2%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>38,675.17</td>
<td>-0.3%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>17,749.70</td>
<td>-0.5%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,044.70</td>
<td>-0.9%</td>
</tr>
</tbody>
</table>
</figure>
The SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was 0.2% lower to $500.96, the SPDR Dow Jones Industrial Average (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) fell 0.3% to $386.90 and the tech-heavy Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.5% to $432.16, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>. 
The Consumer Staples Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLP#NYSE">XLP</a>), outperformed, up 0.5%, while the Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>) was the laggard, down 1.4%. 
<h2 class="wp-block-heading">Friday's Stock Movers</h2>
<ul>
<li>Bio-Rad Laboratories Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) rose over 7%, marking the largest one-day rise among S&amp;P 500 stocks after the company released stronger-than-expected results last quarter. </li>
<li>Digital Realty Corp. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) fell 7.6% after fourth-quarter results missed projections. </li>
<li>Other companies reacting to earnings were Applied Materials Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NYSE">AMAT</a>), up 7%, Vulcan Materials Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>), Kinsale Capital Group Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KNSL#NYSE">KNSL</a>), up 18%, The Trade Desk Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), up 18%, Coinbase Global Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>), up 15%, Toast Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TOST#NYSE">TOST</a>), up 15%, ShockWave Medical Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SWAV#NASDAQ">SWAV</a>), up 13%, Roku Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>), down 23%, Dropbox Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DBX#NASDAQ">DBX</a>), down 21% and DoorDash Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>), down 9%. </li>
</ul>
Read now: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/02/37183515/roku-stock-down-22-despite-almost-perfect-quarter-analyst-expects-stock-to-be-range">Roku Stock Down 22% Despite &#8216;Almost Perfect Quarter&#8217;: Analyst Expects Stock To Be &#8216;Range-Bound Until Platform Growth Returns&#8217;</a>
Illustration created using artificial intelligence via MidJourney.

Tech Stocks Ease On Hot PPI, Yields Rise, Microsoft, Amazon Snap 5-Week Positive Streak: What's Driving Markets Friday?

Bio-Rad Laboratories shares are trading higher following Q4 earnings.

RBC Capital analyst Conor McNamara maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Outperform and lowers the price target from $484 to $480.

RBC Capital Maintains Outperform on Bio-Rad Laboratories, Lowers Price Target to $480

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.
Shares of Applied Materials, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/amat#NASDAQ">AMAT</a>) rose sharply in today&rsquo;s session after the company reported better-than-expected first-quarter financial results and <a href="https://www.benzinga.com/markets/equities/24/02/37178463/applied-materials-surges-after-q1-earnings-why-the-stock-chart-is-bullish">issued second-quarter guidance</a>.
Applied Materials reported quarterly earnings of $2.13 per share which beat the analyst consensus estimate of $1.91 by 11.52%. The company reported quarterly sales of $6.71 billion, beating the analyst consensus estimate of $6.48 billion by 3.55%, and representing a 0.47% decrease over sales of $6.74 billion from the same period last year.
Applied Materials shares jumped 8.3% to $203.27 on Friday.
Here are some other big stocks recording gains in today&rsquo;s session.
<ul>
<li>PRA Group, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/praa#NASDAQ">PRAA</a>) shares jumped 23.4% to $30.25 following upbeat results.</li>
<li>The Trade Desk, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/ttd#NASDAQ">TTD</a>) shares gained 21% to $91.66 after the company reported mixed fourth-quarter financial results.</li>
<li>Nano-X Imaging Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nnox#NASDAQ">NNOX</a>) rose 19% to $11.31. Nvidia recently reported a 59,632 share stake in the company.</li>
<li>Backblaze, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/blze#NASDAQ">BLZE</a>) jumped 17.2% to $9.55 after the company reported better-than-expected fourth-quarter financial results and issued full year 2024 revenue guidance above estimates.</li>
<li>Toast, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/tost#NYSE">TOST</a>) climbed 16.6% to $22.39 after the company reported better-than-expected fourth-quarter financial results and issued first-quarter adjusted subscription services and financial technology solutions guidance. Also the company authorized a $250 million share repurchase program.</li>
<li>Coinbase Global, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/coin#NASDAQ">COIN</a>) shares gained 15.8% to $191.79 as the company reported better-than-expected financial results for its fourth quarter on Thursday.</li>
<li>Nayax Ltd. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/nyax#NASDAQ">NYAX</a>) climbed 15.6% to $30.99. Nayax is expected to report fourth-quarter earnings on Feb. 28, 2024.</li>
<li>Kinsale Capital Group, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/knsl#NYSE">KNSL</a>) rose 13.1% to $495.00 following upbeat quarterly results.</li>
<li>Gyre Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/gyre#NASDAQ">GYRE</a>) gained 11.9% to $17.88.</li>
<li>Texas Roadhouse, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/txrh#NASDAQ">TXRH</a>) rose 10% to $147.30 after the company reported better-than-expected fourth-quarter GAAP EPS results. Also, Wedbush and Stephens &amp; Co raised their respective price targets on the stock.</li>
<li>HireRight Holdings Corporation (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/hrt#NYSE">HRT</a>) climbed 9.8% to $14.12 as the company agreed to be acquired by General Atlantic and Stone Point Capital.</li>
<li>Shockwave Medical, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/swav#NASDAQ">SWAV</a>) gained 9.6% to $258.98 after the company reported better-than-expected fourth-quarter financial results.</li>
<li>Sarepta Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/srpt#NASDAQ">SRPT</a>) surged 7.9% to $134.73 after the FDA accepted and filed the company&#39;s efficacy supplement to the Biologics License Application for ELEVIDYS.</li>
<li>Bio-Rad Laboratories, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/bio#NYSE">BIO</a>) jumped 7.1% to $352.10 following upbeat earnings.</li>
<li>Vulcan Materials Company (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/vmc#NYSE">VMC</a>) gained 5.6% to $256.08 following strong results.</li>
<li>Artivion, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aort#NASDAQ">AORT</a>) gained 4.1% to $18.78 following strong quarterly results.</li>
<li>DT Midstream, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/dtm#NYSE">DTM</a>) rose 4% to $54.51 following upbeat earnings.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/24/02/37156040/top-4-health-care-stocks-you-may-want-to-dump-in-february"> Top 4 Health Care Stocks You May Want To Dump In February </a>

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) reported its Q4 earnings results on Thursday, February 15, 2024 at 04:15 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Bio-Rad Laboratories beat estimated earnings by 9.93%, reporting an EPS of $3.1 versus an estimate of $2.82.
Revenue was down $49.10 million from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company missed on EPS by $0.45 which was followed by a 7.15% drop in the share price the next day.
Here's a look at Bio-Rad Laboratories's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.78</td>
<td>2.55</td>
<td>3.54</td>
<td>3.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.33</td>
<td>3</td>
<td>3.34</td>
<td>3.31</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>689.57M</td>
<td>687.88M</td>
<td>689.83M</td>
<td>742.25M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>632.12M</td>
<td>681.10M</td>
<td>676.84M</td>
<td>730.29M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Bio-Rad Laboratories <a href="https://www.benzinga.com/quote/BIO/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Bio-Rad Laboratories: Q4 Earnings Insights

Guidance

Bio-Rad Laboratories Sees FY24 Non-GAAP Currency-Neutral Revenue Growth ~1.0%-2.5%; Non-GAAP Operating Margin ~13.5%-14.0%

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) reported quarterly earnings of $3.10 per share which beat the analyst consensus estimate of $2.82 by 9.93 percent. The company reported quarterly sales of $681.20 million which missed the analyst consensus estimate of $685.09 million by 0.57 percent. This is a 6.72 percent decrease over sales of $730.29 million the same period last year.

Earnings Beats

Earnings Misses

Bio-Rad Laboratories Q4 2023 Adj EPS $3.10 Beats $2.82 Estimate, Sales $681.20M Miss $685.09M Estimate

AGIO

ALKS

ALLT

ALNY

APPN

ARCH

ATRC

AUPH

BJRI

BPMC

CBRE

CGNX

CLBT

CMBM

COHU

CORT

CRBG

CROX

CWST

DKNG

DNOW

EDRY

ELME

EPAM

GLOB

Hannon Armstrong Sustainable Infrastructure Capital

HASI

HOUS

HTGC

IDCC

IRDM

IREN

IRWD

ITGR

JMIA

KELYA

KELYB

LBTYA

LECO

Laboratory Corporation Of America Holdings

MERC

MTRN

MYTE

NSIT

NVMI

OPEN

ORAN

OTLY

PACB

PCOR

PDFS

PENN

PRTA

RARE

RELX

RPRX

Earnings Scheduled For February 15, 2024

Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) is set to give its latest quarterly earnings report on Thursday, 2024-02-15. Here's what investors need to know before the announcement.
Analysts estimate that Bio-Rad Laboratories will report an earnings per share (EPS) of $2.82. 
Bio-Rad Laboratories bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Past Earnings Performance</h3>
Last quarter the company missed EPS by $0.45, which was followed by a 7.15% drop in the share price the next day.
Here's a look at Bio-Rad Laboratories's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
<th>Q1 2023</th>
<th>Q4 2022</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>2.78</td>
<td>2.55</td>
<td>3.54</td>
<td>3.45</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>2.33</td>
<td>3</td>
<td>3.34</td>
<td>3.31</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-7.15%</td>
<td>-0.45%</td>
<td>-16.72%</td>
<td>5.99%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1707937283_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Bio-Rad Laboratories were trading at $316.1 as of February 13. Over the last 52-week period, shares are down 28.78%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/BIO/earnings">To track all earnings releases for Bio-Rad Laboratories visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Preview: Bio-Rad Laboratories's Earnings

Shares of lifesciences and medical equipment stocks are trading higher following strong earnings from Sartorius.

The S&amp;P 500 index recently surged to new all-time highs, experiencing a remarkable gain of nearly 20% in the past three months. This surge can be attributed to the influence of artificial intelligence, optimistic expectations for a robust earnings season and the anticipation of interest rate cuts by <a href="https://www.benzinga.com/markets/equities/24/01/36700326/s-p-500-index-reaches-all-time-highs-ai-rate-cut-hopes-cement-the-milestone">the Federal Reserve in 2024.</a>
Amidst this significant milestone, investors are left pondering whether there are still untapped opportunities within the index that tracks the performance of the largest 500 U.S. companies.
Traditional valuation metrics commonly used to determine whether a stock is over or undervalued include the price-to-earnings ratio (P/E) and the price-to-sales ratio (P/S).
Alternatively, another approach is to examine the upside potential as projected by Wall Street analysts for the upcoming year. This involves looking at the percentage gap between their one-year median price target and the current market prices.
Here are the S&amp;P 500 stocks currently displaying the most significant upside potential, as their price targets significantly exceed their current market valuations.
<h2 class="wp-block-heading">Top 10 Stocks Positioned For 2024 Rally: What Wall Street Analysts See That Investors Might Not</h2>
Warner Bros. Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBD#NASDAQ">WBD</a>) has a substantial gap between its year-ahead analyst median price target and the current market price. This means analysts have a more optimistic outlook for the stock&#8217;s future performance compared to its current trading price.
Second in this ranking, there is First Solar Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>), with a 47.7% year-ahead upside. Third is Marathon Oil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>) with a 45% upside potential. 
<figure class="wp-block-table"> 
<table>
<thead>
<tr>
<th>Company Name</th>
<th>Market Cap</th>
<th>Price Change % (YTD)</th>
<th>Price Target % (Med)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warner Bros. Discovery, Inc. </td>
<td>$25.68B</td>
<td>-7.47%</td>
<td>51.95%</td>
</tr>
<tr>
<td>First Solar, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NASDAQ">FSLR</a>)</td>
<td>$16.38B</td>
<td>-11.01%</td>
<td>47.74%</td>
</tr>
<tr>
<td>Marathon Oil Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>)</td>
<td>$13.19B</td>
<td>-6.73%</td>
<td>45.11%</td>
</tr>
<tr>
<td>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</td>
<td>$13.35B</td>
<td>-1.37%</td>
<td>43.75%</td>
</tr>
<tr>
<td>Bunge Global SA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BG#NYSE">BG</a>)</td>
<td>$13.14B</td>
<td>-10.41%</td>
<td>43.73%</td>
</tr>
<tr>
<td>Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>)</td>
<td>$14.47B</td>
<td>-14.67%</td>
<td>41.94%</td>
</tr>
<tr>
<td>Newmont Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NEM#NYSE">NEM</a>)</td>
<td>$40.77B</td>
<td>-14.54%</td>
<td>40.94%</td>
</tr>
<tr>
<td>Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>)</td>
<td>$23.32B</td>
<td>-8.13%</td>
<td>39.51%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>)</td>
<td>$9.22B</td>
<td>-2.30%</td>
<td>39.48%</td>
</tr>
<tr>
<td>Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>)</td>
<td>$31.93B</td>
<td>-1.33%</td>
<td>37.37%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Stocks with the largest upside potential as of Jan. 23, 2024</figcaption></figure>
Read Now: <a href="https://www.benzinga.com/markets/asia/24/01/36738324/chinas-market-rescue-a-bold-278-billion-stabilization-plan-in-play-amid-deepening-crisis">China&#8217;s Market Rescue: A Bold $278 Billion Stabilization Plan In Play Amid Deepening Crisis</a>

APTV

FSLR

10 S&P 500 Stocks With Over 40% Upside Potential: Hidden Gems Or Value Traps?

The S&amp;P 500 Index has risen by 19% year-to-date, with three weeks remaining in the year and just a five percentage point gap from the all-time highs <a href="https://www.benzinga.com/markets">reached in January 2022.</a>
Despite the impressive rally in the broader stock market, closely followed by the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), only 281 stocks comprising the index, or 56% of the total, have shown positive performance since the beginning of the year. 
In other terms, 44% of S&amp;P 500 companies took the path of retreat, a rare sight in a year when the stock market&#8217;s returns were nothing short of a feast.
Investors seeking so-called &#8220;laggards&#8221; — Goldman Sachs recently dedicated an <a href="https://www.benzinga.com/analyst-ratings/analyst-color/23/12/36113326/2024s-potential-stock-surprises-goldman-sachs-unveils-s-p-500-laggards-for-major-ga">analysis</a> to this topic — are looking for the untapped potential hidden in S&amp;P 500 stocks that have remained well outside the bullish eye of the market in 2023.
<h2 class="wp-block-heading">Hunting For Laggards In A Bullish Jungle: Top 10 S&amp;P 500 Upside Picks</h2>
The stock that currently offers the highest upside potential compared to the median price targets set by Wall Street analysts is Moderna Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>). Moderna is trading at $78 per share, while the one-year median price target is $127.50, representing a 58% potential upside.
Not far behind in terms of potential is First Solar Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FSLR#NYSE">FSLR</a>), ranking second on this list with a 56% upside potential. Third, with a 52% upside, is Albemarle Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALB#NYSE">ALB</a>).
Looking at the top 10, what stands out is the presence of three stocks related to hotels and casinos: Wynn Resort Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WYNN#NYSE">WYNN</a>), Las Vegas Sands Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LVS#NYSE">LVS</a>), and Caesars Entertainment Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NYSE">CZR</a>), with potential upsides of 48%, 45% and 43%, respectively.
Only three stocks in the top 10 have shown positive performance year-to-date, including Wynn Resort Ltd., Caesars Entertainment Inc., and Warner Bros Discovery Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDB#NASDAQ">WDB</a>).
<figure class="wp-block-table"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Industry</th>
<th>Last Price</th>
<th>Median Price Target</th>
<th>Target %</th>
<th>Price Change % (YTD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Moderna, Inc.</td>
<td>Biotechnology</td>
<td>78.83</td>
<td>127.50</td>
<td>58.19%</td>
<td>-56.44%</td>
</tr>
<tr>
<td>First Solar, Inc.</td>
<td>Semiconductors and Semiconductor Equipment</td>
<td>143.66</td>
<td>227.00</td>
<td>56.24%</td>
<td>-4.07%</td>
</tr>
<tr>
<td>Albemarle Corporation</td>
<td>Chemicals</td>
<td>122.37</td>
<td>180.00</td>
<td>52.16%</td>
<td>-43.56%</td>
</tr>
<tr>
<td>Aptiv PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>)</td>
<td>Automobile Components</td>
<td>81.09</td>
<td>121.00</td>
<td>49.60%</td>
<td>-12.73%</td>
</tr>
<tr>
<td>Wynn Resorts, Limited</td>
<td>Hotels, Restaurants and Leisure</td>
<td>83.21</td>
<td>122.00</td>
<td>48.06%</td>
<td>1.13%</td>
</tr>
<tr>
<td>Incyte Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INCY#NASDAQ">INCY</a>)</td>
<td>Biotechnology</td>
<td>55.16</td>
<td>82.00</td>
<td>47.96%</td>
<td>-31.21%</td>
</tr>
<tr>
<td>Warner Bros. Discovery, Inc.</td>
<td>Entertainment</td>
<td>11.09</td>
<td>16.00</td>
<td>46.52%</td>
<td>16.56%</td>
</tr>
<tr>
<td>Las Vegas Sands Corp.</td>
<td>Hotels, Restaurants and Leisure</td>
<td>45.09</td>
<td>65.00</td>
<td>44.99%</td>
<td>-5.99%</td>
</tr>
<tr>
<td>Caesars Entertainment, Inc.</td>
<td>Hotels, Restaurants and Leisure</td>
<td>43.73</td>
<td>62.00</td>
<td>42.82%</td>
<td>4.76%</td>
</tr>
<tr>
<td>Bio-Rad Laboratories, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>)</td>
<td>Life Sciences Tools and Services</td>
<td>309.62</td>
<td>441.00</td>
<td>42.03%</td>
<td>-26.23%</td>
</tr>
</tbody>
</table>
</figure>
<h2 class="wp-block-heading">Look Who&#8217;s In 17th Place</h2>
Beyond the glittering top 10, there&#8217;s a basket of stocks offering compelling upside potential, ranging from 30% to 41%.
What truly raises eyebrows is the appearance of NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) in the 17th position.
With a jaw-dropping year-to-date performance of 215%, Nvidia has been the star of the S&amp;P 500 in 2023. 
Wall Street&#8217;s appetite for the chipmaker giant seems insatiable. Nvidia&#8217;s median price target set by analysts, with a one-year horizon in mind, stands at $630 per share. This projection implies a rally of 38.45% from its current trading price.
Diving into the mix, we find a significant presence of stocks hailing from the energy sector. 
Names like APA Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APA#NYSE">APA</a>), Halliburton Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>), Schlumberger NV (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SLB#NYSE">SLB</a>), and Marathon Oil Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRO#NYSE">MRO</a>) each flaunt an enticing 40% upside potential, while Baker Hughes Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKR#NYSE">BKR</a>) screens a 31% upside potential.
<figure class="wp-block-table"> 
<table>
<thead>
<tr>
<th>Name</th>
<th>Industry</th>
<th>Last Price</th>
<th>Median Price Target</th>
<th>Target %</th>
<th>Price Change % (YTD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>APA Corporation </td>
<td>Oil, Gas and Consumable Fuels</td>
<td>34.12</td>
<td>48.00</td>
<td>41.05%</td>
<td>-26.71%</td>
</tr>
<tr>
<td>Halliburton Company</td>
<td>Energy Equipment and Services</td>
<td>34.80</td>
<td>49.00</td>
<td>40.56%</td>
<td>-11.56%</td>
</tr>
<tr>
<td>Schlumberger Limited </td>
<td>Energy Equipment and Services</td>
<td>48.90</td>
<td>69.00</td>
<td>40.44%</td>
<td>-8.55%</td>
</tr>
<tr>
<td>Marathon Oil Corporation </td>
<td>Oil, Gas and Consumable Fuels</td>
<td>23.76</td>
<td>33.00</td>
<td>40.19%</td>
<td>-12.19%</td>
</tr>
<tr>
<td>MGM Resorts International (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MGM#NYSE">MGM</a>)</td>
<td>Hotels, Restaurants and Leisure</td>
<td>40.12</td>
<td>55.00</td>
<td>39.70%</td>
<td>19.49%</td>
</tr>
<tr>
<td>United Airlines Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UAL#NASDAQ">UAL</a>)</td>
<td>Passenger Airlines</td>
<td>41.92</td>
<td>57.00</td>
<td>39.26%</td>
<td>11.13%</td>
</tr>
<tr>
<td>NVIDIA Corporation</td>
<td>Semiconductors and Semiconductor Equipment</td>
<td>463.05</td>
<td>630.00</td>
<td>38.45%</td>
<td>215.83%</td>
</tr>
<tr>
<td>The Cigna Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>)</td>
<td>Health Care Providers and Services</td>
<td>256.13</td>
<td>351.00</td>
<td>36.32%</td>
<td>-22.62%</td>
</tr>
<tr>
<td>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>)</td>
<td>Distributors</td>
<td>45.16</td>
<td>61.50</td>
<td>35.70%</td>
<td>-15.39%</td>
</tr>
<tr>
<td>Corteva, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>)</td>
<td>Chemicals</td>
<td>44.29</td>
<td>59.50</td>
<td>34.77%</td>
<td>-24.71%</td>
</tr>
<tr>
<td>Alaska Air Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALK#NYSE">ALK</a>)</td>
<td>Passenger Airlines</td>
<td>36.00</td>
<td>48.00</td>
<td>34.57%</td>
<td>-16.35%</td>
</tr>
<tr>
<td>BorgWarner Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>)</td>
<td>Automobile Components</td>
<td>32.95</td>
<td>44.00</td>
<td>34.43%</td>
<td>-17.96%</td>
</tr>
<tr>
<td>Align Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGN#NASDAQ">ALGN</a>)</td>
<td>Health Care Equipment and Supplies</td>
<td>217.97</td>
<td>290.00</td>
<td>33.72%</td>
<td>3.58%</td>
</tr>
<tr>
<td>Live Nation Entertainment, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LYV#NYSE">LYV</a>)</td>
<td>Entertainment</td>
<td>82.64</td>
<td>110.00</td>
<td>33.27%</td>
<td>18.32%</td>
</tr>
<tr>
<td>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>)</td>
<td>Biotechnology</td>
<td>237.89</td>
<td>311.00</td>
<td>32.98%</td>
<td>-14.37%</td>
</tr>
<tr>
<td>Baker Hughes Company </td>
<td>Energy Equipment and Services</td>
<td>31.97</td>
<td>41.75</td>
<td>31.04%</td>
<td>8.16%</td>
</tr>
<tr>
<td>Johnson Controls International plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JCI#NYSE">JCI</a>)</td>
<td>Building Products</td>
<td>55.22</td>
<td>72.00</td>
<td>30.81%</td>
<td>-13.75%</td>
</tr>
</tbody>
</table>
</figure>
Read Now: <a href="https://www.benzinga.com/general/23/12/36135898/microsoft-nasdaq-msft-vs-meta-nasdaq-meta-analyzing-1-000-investments-from-may-18-2012">Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) Vs. Meta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) — Analyzing $1,000 Investments From May 18, 2012</a>

ALGN

BIIB

CTVA

INCY

MRNA

NVDA

WYNN

S&P 500's Hidden Gems: 27 Stocks With 30%+ Upside Potential According To Wall Street Analyst Targets

UBS analyst Dan Leonard initiates coverage on Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy rating and announces Price Target of $395.

Initiation

UBS Initiates Coverage On Bio-Rad Laboratories with Buy Rating, Announces Price Target of $395

Bio-Rad Laboratories (BIO) has shared an update. Dr. Andrew Last, Executive Vice President and Chief Operating Officer of Bio-Rad Laboratories, pla...

Bio-Rad Exec VP Andrew Last Announces Retirement Plans

Cardinal Health, Cigna, Merck among top healthcare Quant picks ahead of Q1 earnings

Oncocyte stock rallies 90% post-market on Bio-Rad partnership

Bio-Rad: A Lackluster Picks-And-Shovels Life Science Company With A Key Investment Kicker

Goldman's debt issuers stocks basket

Danaher gains as Q1 results exceed expectations

How is SPY stock faring? The SPDR S&P 500 ETF Trust is up 1.68% in the past 5 days and has risen about 26% over the past year. According to TipRanks'

SPY ETF Update, 4/25/2024

Bio-Rad Laboratories (BIO) has issued an update. Simon May, a key executive at Bio-Rad Laboratories, has announced his resignation to take on a new...

Bio-Rad Laboratories: Executive Transition and Shareholder Decisions

How is SPY stock faring? The SPDR S&P 500 ETF Trust is up 1.37% in the past 5 days and has risen about 24% over the past year. According to TipRank...

SPY ETF Update, 4/29/2024

RBC Capital analyst Conor McNamara maintained a Buy rating on Bio-Rad Laboratories (BIO – Research Report) on April 29 and set a price target of $4...

Bio-Rad Laboratories (BIO) Receives a Buy from RBC Capital

ABNB

AMGN

AVGO

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Bio-Rad Laboratories Stock (NYSE:BIO), Short Interest Report

People Also Watch